Anzahl der Publikationen: 4
Zeitschriftenartikel
Warren, Richard B.; Strober, Bruce ORCID: https://orcid.org/0000-0002-8394-2057; Silverberg, Jonathan I. ORCID: https://orcid.org/0000-0003-3686-7805; Guttman, Emma ORCID: https://orcid.org/0000-0002-9363-324X; Andres, Philippe; Felding, Jakob; Tutkunkardas, Deniz ORCID: https://orcid.org/0000-0002-9390-6105; Kjøller, Kim; Sommer, Morten O. A. und French, Lars E. ORCID: https://orcid.org/0000-0002-4629-1486
(2023):
Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets.
In: Journal of the European Academy of Dermatology and Venereology, Bd. 37, Nr. 4: S. 711-720
[PDF, 236kB]
Blauvelt, Andrew; Langley, Richard G.; Lacour, Jean-Philippe; Toth, Darryl; Laquer, Vivian; Beissert, Stefan; Wollenberg, Andreas; Herranz, Pedro; Pink, Andrew E.; Peris, Ketty; Fangel, Stine; Gjerum, Le; Corriveau, Joshua; Saeki, Hidehisa; Warren, Richard B.; Simpson, Eric und Reich, Kristian
(2022):
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
In: Journal of the American Academy of Dermatology, Bd. 87, Nr. 4: S. 815-824
Simpson, Eric L.; Merola, Joseph F.; Silverberg, Jonathan I.; Reich, Kristian; Warren, Richard B.; Staumont-Salle, Delphine; Girolomoni, Giampiero; Papp, Kim; Bruin-Weller, Marjolein de; Thyssen, Jacob P.; Zachariae, Rebecca; Olsen, Christiana K. und Wollenberg, Andreas
(2022):
Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.
In: British Journal of Dermatology, Bd. 187, Nr. 6: S. 888-899
Lebwohl, Mark; Kircik, Leon; Lacour, Jean-Philippe; Liljedahl, Monika; Lynde, Charles; Morch, Marie Holst; Papp, Kim A.; Perrot, Jean-Luc; Gold, Linda Stein; Takhar, Amrit; Thaci, Diamant; Warren, Richard B. und Wollenberg, Andreas
(2021):
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial).
In: Journal of the American Academy of Dermatology, Bd. 84, Nr. 5: S. 1269-1277
Diese Liste wurde am
Sat Dec 21 19:57:21 2024 CET
erstellt.